Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology
Aspatwar A, Tolvanen MEE, Barker H, Syrjänen L, Valanne S, Purmonen S, Waheed A, Sly WS and Parkkila S
Carbonic anhydrases in metazoan model organisms: molecules, mechanisms, and physiology
Aspatwar A, Tolvanen MEE, Barker H, Syrjänen L, Valanne S, Purmonen S, Waheed A, Sly WS and Parkkila S
During the past three decades, mice, zebrafish, fruit flies, and have been the primary model organisms used for the study of various biological phenomena. These models have also been adopted and developed to investigate the physiological roles of carbonic anhydrases (CAs) and carbonic anhydrase-related proteins (CARPs). These proteins belong to eight CA families and are identified by Greek letters: α, β, γ, δ, ζ, η, θ, and ι. Studies using model organisms have focused on two CA families, α-CAs and β-CAs, which are expressed in both prokaryotic and eukaryotic organisms with species-specific distribution patterns and unique functions. This review covers the biological roles of CAs and CARPs in light of investigations performed in model organisms. Functional studies demonstrate that CAs are not only linked to the regulation of pH homeostasis, the classical role of CAs, but also contribute to a plethora of previously undescribed functions.
α-hydroxytropolones Inhibit RNase H1 Noncompetitively Despite Binding in the Active Site
Ponzar NL, Tajwar R, Pozzi N and Tavis JE
α-hydroxytropolones Inhibit RNase H1 Noncompetitively Despite Binding in the Active Site
Ponzar NL, Tajwar R, Pozzi N and Tavis JE
Human immunodeficiency virus (HIV) and Hepatitis B virus (HBV) ribonucleases H (RNase H) are type 1 RNases H that are promising drug targets because inhibiting their activity blocks viral replication. RNases H cleave RNA in RNA/DNA hybrids. Eukaryotic RNase H1 is an essential protein and probable off-target enzyme for viral RNase H inhibitors. α-hydroxytropolones (αHTs) comprise an anti-RNase H inhibitor class that can inhibit the HIV, HBV, and human RNases H1. These compounds work by binding the RNase H active site by chelating the catalytic divalent metal cofactors. We hypothesized that a better understanding of RNase H1 inhibition will help development of compounds selective for the viral RNases H. To this end, we expressed and purified recombinant human RNase H1 and determined its inhibition mechanism(s) in steady-state kinetics by two αHTs, 110 and 404 (Fig. 1). Inhibition was not competitive with a 12-mer RNA/DNA substrate, but the turnover rate was reduced despite inhibitor binding to the active site (Fig. 2). 110 and 404displayed inhibition constants of 9 μM and 3 μM in saturating substrate concentrations, respectively, and these values were elevated 2-3-fold in very low substrate. Saturating 110and 404concentrations modestly reduced the apparent substrate binding constant (K ) from 90 nM to ~30 nM, while reducing the turnover rate (k = 0.17 s ) ~20-fold. We found that 110enhanced affinity of RNase H1 for substrate by 4-fold using a fluorescence polarization (FP) substrate binding assay with Ca instead of Mg to prevent RNA cleavage. 404, on the other hand, competed with substrate in binding assays, raising the substrate's K ~7-fold from 24 nM without compound to ~150 nM. Induced fit docking studies in the Schrödinger suite suggest 110 binds to the active site metals as expected, while the substrate is still capable of binding via RNase H1's high-affinity auxiliary RNA/DNA hybrid binding domain (HBD) and substrate binding groove within the RNase H domain. 110 made favorable contacts with both enzyme and substrate, stabilizing an ESI complex. 404, on the other hand, occupies much of the substrate binding groove as well as the active site due to its larger structure. This would explain why 404 competes with substrate binding, while 110enhances substrate binding. The reason the K decreased with 404 despite its competitive behavior in substrate binding assays is not clear. However, we hypothesize that 404locally competes with the substrate for the RNase H1 active site and the substrate binding groove within the RNase H domain without interfering with the HBD:substrate interface. This could lower the overall ES affinity. However, we speculate that if substrate release is slow relative to RNA hydrolysis and product release, the compound could behave uncompetitively in kinetics assays by inhibiting the breakdown of the ES complex through catalysis, only permitting enzyme-substrate dissociation via the putatively slow substrate release pathway. Thus, these results illustrate that non-competitive steady-state kinetics may be observed without an allosteric inhibitor binding site. This may be common to active-site inhibitors of enzymes with auxiliary substrate binding domains.
Neuronal KCNQ2/3 channels are recruited to lipid raft microdomains by palmitoylation of BACE1
Dai G
Neuronal KCNQ2/3 channels are recruited to lipid raft microdomains by palmitoylation of BACE1
Dai G
β-Secretase 1 (β-site amyloid precursor protein [APP]-cleaving enzyme 1, BACE1) plays a crucial role in the amyloidogenesis of Alzheimer's disease (AD). BACE1 was also discovered to act like an auxiliary subunit to modulate neuronal KCNQ2/3 channels independently of its proteolytic function. BACE1 is palmitoylated at its carboxyl-terminal region, which brings BACE1 to ordered, cholesterol-rich membrane microdomains (lipid rafts). However, the physiological consequences of this specific localization of BACE1 remain elusive. Using spectral Förster resonance energy transfer (FRET), BACE1 and KCNQ2/3 channels were confirmed to form a signaling complex, a phenomenon that was relatively independent of the palmitoylation of BACE1. Nevertheless, palmitoylation of BACE1 was required for recruitment of KCNQ2/3 channels to lipid-raft domains. Two fluorescent probes, designated L10 and S15, were used to label lipid-raft and non-raft domains of the plasma membrane, respectively. Coexpressing BACE1 substantially elevated FRET between L10 and KCNQ2/3, whereas the BACE1-4C/A quadruple mutation failed to produce this effect. In contrast, BACE1 had no significant effect on FRET between S15 probes and KCNQ2/3 channels. A reduction of BACE1-dependent FRET between raft-targeting L10 probes and KCNQ2/3 channels by applying the cholesterol-extracting reagent methyl-β-cyclodextrin (MβCD), raft-disrupting general anesthetics, or pharmacological inhibitors of palmitoylation, all supported the hypothesis of the palmitoylation-dependent and raft-specific localization of KCNQ2/3 channels. Furthermore, mutating the four carboxyl-terminal cysteines (4C/A) of BACE1 abolished the BACE1-dependent increase of FRET between KCNQ2/3 and the lipid raft-specific protein caveolin 1. Taking these data collectively, we propose that the AD-related protein BACE1 underlies the localization of a neuronal potassium channel.
Alpha-hydroxytropolones are noncompetitive inhibitors of human RNase H1 that bind to the active site and modulate substrate binding
Ponzar NL, Tajwar R, Pozzi N and Tavis JE
Alpha-hydroxytropolones are noncompetitive inhibitors of human RNase H1 that bind to the active site and modulate substrate binding
Ponzar NL, Tajwar R, Pozzi N and Tavis JE
The ribonucleases H (RNases H) of HIV and hepatitis B virus are type 1 RNases H that are promising drug targets because inhibiting their activity blocks viral replication. Eukaryotic ribonuclease H1 (RNase H1) is an essential protein and a probable off-target enzyme for viral RNase H inhibitors. α-hydroxytropolones (αHTs) are a class of anti-RNase H inhibitors that can inhibit the HIV, hepatitis B virus, and human RNases H1; however, it is unclear how these inhibitors could be developed to distinguish between these enzymes. To accelerate the development of selective RNase H inhibitors, we performed biochemical and kinetic studies on the human enzyme, which was recombinantly expressed in Escherichia coli. Size-exclusion chromatography showed that free RNase H1 is monomeric and forms a 2:1 complex with a substrate of 12 bp. FRET heteroduplex cleavage assays were used to test inhibition of RNase H1 in steady-state kinetics by two structurally diverse αHTs, 110 and 404. We determined that turnover rate was reduced, but inhibition was not competitive with substrate, despite inhibitor binding to the active site. Given the compounds' reversible binding to the active site, we concluded that traditional noncompetitive and mixed inhibition mechanisms are unlikely. Instead, we propose a model in which, by binding to the active site, αHTs stabilize an inactive enzyme-substrate-inhibitor complex. This new model clarifies the mechanism of action of αHTs against RNase H1 and will aid the development of RNase H inhibitors selective for the viral enzymes.
Hepatic stellate cells in physiology and pathology
Kamm DR and McCommis KS
Hepatic stellate cells in physiology and pathology
Kamm DR and McCommis KS
Hepatic stellate cells (HSCs) comprise a minor cell population in the liver but serve numerous critical functions in the normal liver and in response to injury. HSCs are primarily known for their activation upon liver injury and for producing the collagen-rich extracellular matrix in liver fibrosis. In the absence of liver injury, HSCs reside in a quiescent state, in which their main function appears to be the storage of retinoids or vitamin A-containing metabolites. Less appreciated functions of HSCs include amplifying the hepatic inflammatory response and expressing growth factors that are critical for liver development and both the initiation and termination of liver regeneration. Recent single-cell RNA sequencing studies have corroborated earlier studies indictaing that HSC activation involves a diverse array of phenotypic alterations and identified unique HSC populations. This review serves to highlight these many functions of HSCs, and to briefly describe the recent genetic tools that will help to thoroughly investigate the role of HSCs in hepatic physiology and pathology.
Human HELB is a processive motor protein that catalyzes RPA clearance from single-stranded DNA
Hormeno S, Wilkinson OJ, Aicart-Ramos C, Kuppa S, Antony E, Dillingham MS and Moreno-Herrero F
Human HELB is a processive motor protein that catalyzes RPA clearance from single-stranded DNA
Hormeno S, Wilkinson OJ, Aicart-Ramos C, Kuppa S, Antony E, Dillingham MS and Moreno-Herrero F
SignificanceSingle-stranded DNA (ssDNA) is a key intermediate in many cellular DNA transactions, including DNA replication, repair, and recombination. Nascent ssDNA is rapidly bound by the Replication Protein A (RPA) complex, forming a nucleoprotein filament that both stabilizes ssDNA and mediates downstream processing events. Paradoxically, however, the very high affinity of RPA for ssDNA may block the recruitment of further factors. In this work, we show that RPA-ssDNA nucleoprotein filaments are specifically targeted by the human HELB helicase. Recruitment of HELB by RPA-ssDNA activates HELB translocation activity, leading to processive removal of upstream RPA complexes. This RPA clearance activity may underpin the diverse roles of HELB in replication and recombination.
Cryo-EM structure of the prothrombin-prothrombinase complex
Ruben EA, Summers B, Rau MJ, Fitzpatrick J and Di Cera E
Cryo-EM structure of the prothrombin-prothrombinase complex
Ruben EA, Summers B, Rau MJ, Fitzpatrick J and Di Cera E
The intrinsic and extrinsic pathways of the coagulation cascade converge to a common step where the prothrombinase complex, comprising the enzyme factor Xa (fXa), the cofactor fVa, Ca2+ and phospholipids, activates the zymogen prothrombin to the protease thrombin. The reaction entails cleavage at two sites, R271 and R320, generating the intermediates prethrombin-2 and meizothrombin, respectively. The molecular basis of these interactions that are central to hemostasis remains elusive. We solved two cryo-EM structures of the fVa-fXa complex, one free on nanodiscs at 5.3 Å resolution and the other bound to prothrombin at near atomic 4.1 Å resolution. In the prothrombin-fVa-fXa complex, the Gla domains of fXa and prothrombin align on a plane with the C1 and C2 domains of fVa for interaction with membranes. Prothrombin and fXa emerge from this plane in curved conformations that bring their protease domains in contact with each other against the A2 domain of fVa. The 672ESTVMATRKMHDRLEPEDEE691 segment of the A2 domain closes on the protease domain of fXa like a lid to fix orientation of the active site. The 696YDYQNRL702 segment binds to prothrombin and establishes the pathway of activation by sequestering R271 against D697 and directing R320 toward the active site of fXa. The structure provides a molecular view of prothrombin activation along the meizothrombin pathway and suggests a mechanism for cleavage at the alternative R271 site. The findings advance our basic knowledge of a key step of the coagulation response and bear broad relevance to other macromolecular interactions in the blood.
Repurposing and optimization of drugs for discovery of novel antifungals
Donlin MJ and Meyers MJ
Repurposing and optimization of drugs for discovery of novel antifungals
Donlin MJ and Meyers MJ
Although fungal diseases are a major and growing public health concern, there are only four major classes of drug to treat primary fungal pathogens. The pipeline of new antifungals in clinical development is relatively thin compared with other disease classes. One approach to rapidly identify and provide novel treatment options is to repurpose existing drugs as antifungals. However, such proposed drug-repurposing candidates often suffer suboptimal efficacy and pharmacokinetics (PK) for fungal diseases. Herein, we briefly review the current antifungal drug pipeline and recent approaches to optimize existing drugs into novel molecules with unique modes of action relative to existing antifungal drug classes.
Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening
Hegazy L, Gill LE, Pyles KD, Kaiho C, Kchouk S, Finck BN, McCommis KS and Elgendy B
Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening
Hegazy L, Gill LE, Pyles KD, Kaiho C, Kchouk S, Finck BN, McCommis KS and Elgendy B
The mitochondrial pyruvate carrier (MPC) is an inner-mitochondrial membrane protein complex that has emerged as a drug target for treating a variety of human conditions. A heterodimer of two proteins, MPC1 and MPC2, comprises the functional MPC complex in higher organisms; however, the structure of this complex, including the critical residues that mediate binding of pyruvate and inhibitors, remain to be determined. Using homology modeling, we identified a putative substrate-binding cavity in the MPC dimer. Three amino acid residues (Phe66 (MPC1) and Asn100 and Lys49 (MPC2)) were validated by mutagenesis experiments to be important for substrate and inhibitor binding. Using this information, we developed a pharmacophore model and then performed a virtual screen of a chemical library. We identified five new non-indole MPC inhibitors, four with IC values in the nanomolar range that were up to 7-fold more potent than the canonical inhibitor UK-5099. These novel compounds possess drug-like properties and complied with Lipinski's Rule of Five. They are predicted to have good aqueous solubility, oral bioavailability, and metabolic stability. Collectively, these studies provide important information about the structure-function relationships of the MPC complex and for future drug discovery efforts targeting the MPC.
TDP-43 Oligomerization and Phase Separation Properties Are Necessary for Autoregulation
Koehler LC, Grese ZR, Bastos ACS, Mamede LD, Heyduk T and Ayala YM
TDP-43 Oligomerization and Phase Separation Properties Are Necessary for Autoregulation
Koehler LC, Grese ZR, Bastos ACS, Mamede LD, Heyduk T and Ayala YM
Loss of TDP-43 protein homeostasis and dysfunction, in particular TDP-43 aggregation, are tied to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 is an RNA binding protein tightly controlling its own expression levels through a negative feedback loop, involving TDP-43 recruitment to the 3' untranslated region of its own transcript. Aberrant TDP-43 expression caused by autoregulation defects are linked to TDP-43 pathology. Therefore, interactions between TDP-43 and its own transcript are crucial to prevent TDP-43 aggregation and loss of function. However, the mechanisms that mediate this interaction remain ill-defined. We find that a central RNA sequence in the 3' UTR, which mediates TDP-43 autoregulation, increases the liquid properties of TDP-43 phase separation. Furthermore, binding to this RNA sequence induces TDP-43 condensation in human cell lysates, suggesting that this interaction promotes TDP-43 self-assembly into dynamic ribonucleoprotein granules. In agreement with these findings, our experiments show that TDP-43 oligomerization and phase separation, mediated by the amino and carboxy-terminal domains, respectively, are essential for TDP-43 autoregulation. According to our additional observations, CLIP34-associated phase separation and autoregulation may be efficiently controlled by phosphorylation of the N-terminal domain. Importantly, we find that specific ALS-associated TDP-43 mutations, mainly M337V, and a shortened TDP-43 isoform recently tied to motor neuron toxicity in ALS, disrupt the liquid properties of TDP-43-RNA condensates as well as autoregulatory function. In addition, we find that M337V decreases the cellular clearance of TDP-43 and other RNA binding proteins associated with ALS/FTD. These observations suggest that loss of liquid properties in M337V condensates strongly affects protein homeostasis. Together, this work provides evidence for the central role of TDP-43 oligomerization and liquid-liquid phase separation linked to RNA binding in autoregulation. These mechanisms may be impaired by TDP-43 disease variants and controlled by specific cellular signaling.